Tsilogianni Zoe, Baker Jonathan R, Papaporfyriou Anastasia, Papaioannou Andrianna I, Papathanasiou Evgenia, Koulouris Nikolaos G, Daly Leah, Ito Kazuhiro, Hillas Georgios, Papiris Spyridon, Bakakos Petros, Loukides Stelios
2nd Department of Respiratory Medicine, Medical School of National and Kapodistrian University of Athens, "Attikon" Hospital, 12462 Athens, Greece.
Airway Disease, National Heart and Lung Institute, Imperial College, London SW3 6LY, UK.
J Clin Med. 2020 Feb 9;9(2):473. doi: 10.3390/jcm9020473.
Sestrin 2, Endocan, and Sirtuin 1 are distinct molecules with some biologic actions associated with asthma pathophysiology. The aim of the present study was to determine the molecular level differences attributable to underlying asthma severity.
We initially recruited 85 asthmatics with a wide spectrum of severity. All of the patients were optimally treated according to current guidelines. Demographics, test results of lung function, and treatment regimes of all patients were recorded. Sestrin 2, Endocan, and Sirtuin 1 were measured in different biological samples (sputum with two processing methods and serum).
A total of 60 patients (35 with severe asthma) were analyzed, since 25 patients failed to produce an adequate sample of sputum. Patients with severe asthma showed significantly higher values for Sestrin 2 [pg/mL], measured in both sputum supernatant and cell pellet, compared to those with mild to moderate asthma [9524 (5696, 12,373) vs. 7476 (4265, 9273) = 0.029, and 23,748 (15,280, 32,742) vs. 10,084 (3349, 21,784), = 0.008, respectively]. No other significant differences were observed. No significant associations were observed between biomarkers, inflammatory cells, and lung function.
Sestrin 2 is increased in patients with severe asthma as part of a mechanism that may modify structural alterations through the imbalance between oxidative stress and antioxidant activity.
硒蛋白2、内脂素和沉默调节蛋白1是具有一些与哮喘病理生理学相关生物学作用的不同分子。本研究的目的是确定潜在哮喘严重程度所致的分子水平差异。
我们最初招募了85例病情严重程度各异的哮喘患者。所有患者均按照现行指南进行了最佳治疗。记录了所有患者的人口统计学资料、肺功能测试结果和治疗方案。在不同的生物样本（两种处理方法的痰液和血清）中检测了硒蛋白2、内脂素和沉默调节蛋白1。
共分析了60例患者（35例重度哮喘患者），因为25例患者未能提供足够的痰液样本。与轻度至中度哮喘患者相比，重度哮喘患者痰液上清液和细胞沉淀中检测到的硒蛋白2 [pg/mL]值显著更高[分别为9524 (5696, 12373) 对7476 (4265, 9273)，P = 0.029；以及23748 (15280, 32742) 对10084 (3349, 21784)，P = 0.008]。未观察到其他显著差异。生物标志物、炎症细胞和肺功能之间未观察到显著关联。
重度哮喘患者体内的硒蛋白2增加，这可能是一种通过氧化应激与抗氧化活性失衡来改变结构改变的机制的一部分。
